naltrexone implant (OLANI) / Go Medical - LARVOL DELTA

NCI-2016-01130: Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer (clinicaltrials.gov) - P2 | N=89 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Aug 2026 ➔ Aug 2027

Trial completion date • Tumor mutational burden • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • BRCA • BRCA1 • BRCA2 • HER-2

NCI 10129: Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations (clinicaltrials.gov) - P2 | N=89 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2026 ➔ Jul 2027

Trial completion date • Anaplastic Astrocytoma • Biliary Cancer • Brain Cancer • Cholangiocarcinoma • Glioblastoma • Glioma • Oncology • Solid Tumor • IDH1 • IDH2

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - P2 | N=70 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2026 ➔ Jul 2027

Trial completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

NRG-GY012: Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone (clinicaltrials.gov) - P2 | N=288 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2027 ➔ Jul 2027

Trial completion date • Carcinosarcoma • Endometrial Adenocarcinoma • Endometrial Cancer • Endometrial Serous Adenocarcinoma • Oncology • Sarcoma • Solid Tumor • Uterine Cancer

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors (clinicaltrials.gov) - P2 | N=24 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2026 ➔ Jul 2027

Trial completion date • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • IDH1 • IDH2

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial (clinicaltrials.gov) - P2 | N=165 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Active, not recruiting

Enrollment closed • Endometrial Cancer • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • BRAF • HRAS • KRAS • MAP2K1 • MAP2K2 • NF1 • NRAS

NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2027 ➔ Jun 2027

Platinum resistant • Trial completion date • Epithelial Ovarian Cancer • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Refractory Ovarian Cancer • Solid Tumor • Urothelial Cancer • BRCA1 • BRCA2 • PD-L1

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Suspended ➔ Active, not recruiting

Enrollment closed • Oncology • Pancreatic Cancer • Solid Tumor • CD4

A021804: Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer (clinicaltrials.gov) - P2 | N=76 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2024 ➔ Feb 2025 | Trial primary completion date: Feb 2024 ➔ Feb 2025

Metastases • Trial completion date • Trial primary completion date • CNS Tumor • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • CD4 • MGMT

A021804: Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer (clinicaltrials.gov) - P2 | N=46 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2025 ➔ Feb 2026 | Trial primary completion date: Feb 2025 ➔ Feb 2026

Trial completion date • Trial primary completion date • CNS Tumor • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • CD4 • MGMT

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working (clinicaltrials.gov) - P2/3 | N=190 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting | N=70 ➔ 190

Enrollment change • Enrollment open • Metastases • Leiomyosarcoma • Oncology • Sarcoma • Solid Tumor • Uterine Cancer • Uterine Leiomyosarcoma

A021804: Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer (clinicaltrials.gov) - P2 | N=46 | Recruiting | Sponsor: National Cancer Institute (NCI) | N=76 ➔ 46

Enrollment change • CNS Tumor • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • CD4 • MGMT

NCI-2017-02296: Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Suspended ➔ Active, not recruiting

Enrollment closed • Tumor mutational burden • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer • ABL1 • ATRX • BAP1 • BARD1 • BRCA1 • BRCA2 • BRD4 • BRIP1 • CCND1 • CHEK1 • CHEK2 • DOT1L • FANCA • FANCC • FANCE • FANCG • FANCL • IKBKE • MLH1 • MSH2 • MSH6 • NPM1 • POLD1 • POLE • RAD51 • SMARCB1 • STK11 • TMB • TP53

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2026 ➔ May 2027

Trial completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Neuroendocrine Carcinoma • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

NRG-GY004: Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - P3 | N=579 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Nov 2026 ➔ Mar 2027

Platinum sensitive • Trial completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=155 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Nov 2026 ➔ Mar 2027

Platinum sensitive • Trial completion date • Breast Cancer • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Peritoneal Cancer • Solid Tumor • Triple Negative Breast Cancer • BRCA • MUC16

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer (clinicaltrials.gov) - P2 | N=70 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Nov 2026 ➔ Mar 2027

Platinum resistant • Platinum sensitive • Trial completion date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2

NCI-2015-01097: A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors (clinicaltrials.gov) - P2 | N=122 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Apr 2026 ➔ Apr 2027

Trial completion date • Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer • EGFR • ER • HER-2 • PGR

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study (clinicaltrials.gov) - P1 | N=13 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2026 ➔ Dec 2026

Trial completion date • Oncology • Solid Tumor • BRCA1 • BRCA2 • BRIP1 • CD4 • FANCA

NCI10217: Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations (clinicaltrials.gov) - P1 | N=39 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2026 ➔ Dec 2026

Biomarker • Trial completion date • Oncology • Solid Tumor • BARD1 • BRCA1 • BRCA2 • BRIP1 • CD4 • FANCA • NBN • PIK3CA • RAD51 • RAD51B • RAD51C • RAD51D

Head Games: Analyzing Sports that Seek Specialty Care for Concussion Management (PAS 2026) - "We found that no sport was significantly over or underrepresented in referrals when comparing concussion rates by sport and gender, suggesting that care is consistent across sports (p-values: baseball = 0.05, basketball = 1.00, cheerleading = 0.11, football = 0.25, judo = 0.77, soccer = 0.43, softball = 0.24, volleyball = 0.15, wrestling = 0.27).Conclusion(s): Our findings indicate that the percentage of athletes receiving specialized care for sports-related concussions is consistent across all sports in Hawai'i, as no sport showed a significant difference in concussion referral rates (all p-values > 0.05). This finding may be due to HCAMP's efforts to improve statewide concussion care through legislation and outreach.Concussion Rate by SportThis chart presents concussion rates across 9 public school sports, comparing the 90 Kapi'olani Concussion Clinic cases to the 822 DOE-reported cases. Concussion rates were calculated by dividing the number of..."

NCI-2017-02296: Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes (clinicaltrials.gov) - P2 | N=60 | Suspended | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Suspended

Trial suspension • Tumor mutational burden • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer • ABL1 • ATRX • BAP1 • BARD1 • BRCA1 • BRCA2 • BRD4 • BRIP1 • CCND1 • CHEK1 • CHEK2 • DOT1L • FANCA • FANCC • FANCE • FANCG • FANCL • IKBKE • MLH1 • MSH2 • MSH6 • NPM1 • POLD1 • POLE • RAD51 • SMARCB1 • STK11 • TMB • TP53

NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Nov 2026 ➔ Mar 2027

Platinum resistant • Trial completion date • Epithelial Ovarian Cancer • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Refractory Ovarian Cancer • Solid Tumor • Urothelial Cancer • BRCA1 • BRCA2 • PD-L1

NCI-2019-03057: Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation (clinicaltrials.gov) - P2 | N=14 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2026 ➔ Mar 2027

Trial completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • IDH1 • IDH2

Deficiencies in the Assessment of Penicillin Allergy in Hospitalized Children in Hawai'i, 2021-2023. (PubMed, Hawaii J Health Soc Welf) - "This retrospective study reviewed records of children hospitalized at Kapi'olani Medical Center for Women and Children in Honolulu, Hawai'i, between January 1, 2021 and June 30, 2023 to assess the frequency of penicillin allergy claims, the appropriateness of their evaluation, and initiation of interventions...Documentation, by the admitting team, of the nature of allergy was incomplete for most (97%) of the hospitalizations, leading to deficient risk stratification, lack of implementation of recommended interventions, and frequent use of second-line antibiotics in 46.8% of those who required antibiotic treatment. While this problem is not unique to Hawai'i, it emphasizes the need for education among local providers to improve outcomes."

Journal • Retrospective data • Allergy • Immunology • Pediatrics